title: [The use of immunomodulating therapy as part of complex treatment of secondary peritonitis induces reduction of inflammation in patients of different age].
abstract: We present experience of using anti-thymocytic immunoglobulin (ATG) in complex therapy of patients with extensive secondary peritonitis at the age of 29-83 years. The research was based on 60 patient cases: 29 (48%) of whom were given anti-thymocytic immunoglobulin (ATG) Antilymfolin in post operative period and 31 patient of the control group who did not receive immunomodulating therapy within the complex treatment. The received data clearly demonstrates the effectiveness of anti-thymocytic immunoglobulin (ATG) usage for normalization of innate immunity indices and inflammation reduction. Immunostimulating effect in patients given anti-thymocytic immunoglobulin (ATG) could be seen on the fourth day of the threatment. The drug is equally effective in patients of young and middle age as well as in patients of elderly and senility age. The positive influence of anti-thymocytic immunoglobulin (ATG) on inflammation is shown with the reduction of CRP, gamma-globuline, alpha1-protein fraction serum levels normalization. The use of Antilymfolin induces the regression of inflammation and apparently improves the quality and duration of treatment and rehabilitation.
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Epifanova
authors.forename: I G
authors.initials: IG
authors.lastname: Koniaev
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Epifanov
authors.forename: V L
authors.initials: VL
authors.lastname: Golubeva
authors.forename: L D
authors.initials: LD
authors.lastname: Serova
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000276:immunology; D003131:Combined Modality Therapy; D004064:Digestive System; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000276:immunology; D056747:Immunomodulation; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D015166:Monitoring, Immunologic; D010538:Peritonitis / Q000209:etiology / Q000276:immunology / Q000628:therapy; D011183:Postoperative Complications; D012422:Rupture, Spontaneous / Q000150:complications; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000961:Antilymphocyte Serum; D007155:Immunologic Factors